home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

3.670 +0.040 (+1.10%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Nasdaq Surges 150 Points; Lowe's Posts Upbeat Earnings ↗

February 26, 2025

Via Benzinga

Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum

February 26, 2025

Via AB Newswire

Traders are paying attention to the gapping stocks in Wednesday's session. ↗

February 26, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Via Chartmill

These stocks are moving in today's pre-market session ↗

February 26, 2025

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

US Stocks Likely To Open Higher Ahead Of Nvidia Earnings: S&P 500's Four-Day Fall Was A 'Non-Event,' Says Expert ↗

February 26, 2025

U.S. stock futures rose on Wednesday following two consecutive days of mixed close this week. All futures advanced in premarket trading.

Via Benzinga

Topics Stocks

Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

February 26, 2025

Via Benzinga

Which stocks are moving after the closing bell on Tuesday? ↗

February 25, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD ↗

February 25, 2025

Enveric Biosciences secures a U.S. patent for non-hallucinogenic mescaline derivatives targeting addiction, ADHD and anxiety.

Via Benzinga

Topics Derivatives Intellectual Property

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

February 25, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease ↗

February 04, 2025

Enveric's Akos Biosciences licensed its cannabinoid-COX-2 conjugate technology to Restoration Biologics for joint disease treatments, including osteoarthritis.

Via Benzinga

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

February 04, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Closing of $5 Million Public Offering

February 03, 2025

From Enveric Biosciences, Inc.

Via Business Wire

What's going on in today's session ↗

January 31, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Dow Edges Lower; Exxon Mobil Earnings Top Views ↗

January 31, 2025

Via Benzinga

Topics Stocks

Which stocks are gapping on Friday? ↗

January 31, 2025

The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings ↗

January 31, 2025

Via Benzinga

These stocks are moving in today's pre-market session ↗

January 31, 2025

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

January 31, 2025

Via Benzinga

Enveric Biosciences Announces Pricing of $5 Million Public Offering

January 30, 2025

From Enveric Biosciences, Inc.

Via Business Wire

What's going on in today's after hours session ↗

January 30, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

January 30, 2025

From Enveric Biosciences

Via Business Wire

Let's take a look at the stocks that are in motion in today's session. ↗

January 29, 2025

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

Via Chartmill

Here are the top movers in Wednesday's session. ↗

January 29, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 29, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 07, 2025

Via Benzinga

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

January 06, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

December 02, 2024

From Enveric Biosciences

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 27, 2024

Via Benzinga

Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results ↗

November 25, 2024

Via Benzinga

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

November 25, 2024

From Enveric Biosciences, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com